Imax Corp. diskutieren
Imax Corp.
WKN: 896801 / Symbol: IMAX / Name: IMAX / Aktie / Hotels & Unterhaltung / Small Cap /
?
-1,23 %
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $24.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Rosenblatt Securities. They now have a $28.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $27.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $24.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its price target raised by analysts at Roth Mkm from $27.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Wedbush.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its price target raised by analysts at Benchmark Co. from $27.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $30.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $30.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Rosenblatt Securities. They now have a $28.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $30.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $32.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $32.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $32.00. They now have an "overweight" rating on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its price target raised by analysts at Rosenblatt Securities from $28.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its price target raised by analysts at Barrington Research from $30.00 to $32.00. They now have an "outperform" rating on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $30.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $32.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
IMAX Co. (NYSE: IMAX) had its "buy" rating re-affirmed by analysts at Rosenblatt Securities. They now have a $35.00 price target on the stock.
Ratings data for IMAX provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Celldex Therapeutics diskutieren